Skip to main content
. 2020 Jan 31;37(3):1049–1064. doi: 10.1007/s12325-020-01235-y

Fig. 6.

Fig. 6

Cumulative meta-analysis assessing the effect of high dose tigecycline on all-cause mortality of severe infections. The sequential monitoring boundary, which assumes a 42% control event rate and a 12% relative risk reduction with 80% power and two-sided α of 5%, has been crossed, indicating that the cumulative evidence is conclusive